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INTRODUCTION
The prevalence of diabetes mellitus（DM）, especial-
ly type 2 diabetes mell itus（T2DM）, is rapidly 
increasing in this modern societies. The long-term 
duration of inadequate control of blood glucose brings 
about the development of microangiopathy such as 
neuropathy, retinopathy and nephropathy. Progression 
of these diabetic complications results in loss of vision 
and needs for renal replacement therapy such as con-
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SUMMARY
Multiple large-scale clinical trials have indicated that sodium glucose cotransporter 2（SGLT2）inhibitors 
reduce the incidence of cardiovascular events, deterioration of renal function and mortality. However, the 
therapeutic effects of SGLT2 inhibitors are supposed to be limited in patients with reduced renal function 
considering the mechanism of their action. In this study, a SGLT2 inhibitor, ipragliflozin was given to 30 
type 2 diabetic patients with nephropathy whose estimated glomerular filtration rate（eGFR）was not 
lower than 30 mL/min/1.73 m2. After 12 to 16 weeks, hemoglobin A1c decreased by 0.6％（p＜0.001）, body 
weight was reduced by 1.8 kg（p＜0.01）and blood pressure was lowered by －10/－6 mmHg（p＜0.001/p
＜0.001）. This was accompanied by reductions in serum uric acid（－0.7 mg/dL, p＜0.001）, triglycerides
（－25 mg/dL, p＝0.028）and g-glutamyl transferase（－8 U/L, p＝0.001）. On the other hand, plasma B-type 
natriuretic peptide also decreased by 12％（p＝0.020）and urinary albumin excretion was reduced by 23％
（p＝0.018）although the eGFR was not significantly changed. It is concluded that ipragliflozin is effective in 
lowering blood glucose even in patients with diabetic kidney disease and is beneficial in improving the 
accompanying obesity and hypertension. In addition, ipragliflozin is thought to have favorable influences on 
the metabolisms of uric acid and lipids. These properties of ipragliflozin is expected to bring about protec-
tive effects against the progression of nephropathy and the development of cardiovascular disease resulting 
in the improvement of prognosis in diabetic patients with mild to moderate chronic kidney disease.
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tinuation of maintenance hemodialysis which greatly 
reduces the patient’s activity of their daily life. In 
addition, DM is a major risk factor for atherosclerosis 
as well and the incidence of cardiovascular diseases 
such as stroke and coronary heart disease. It is sever-
al-fold higher in patients with DM than in non-diabet-
ic subjects 1）. The complications of such cardiovascular 
diseases are the major causes of mortality in patients 
with DM. Therefore, the care should be directed to 
not only in lowering the blood glucose but also pre-
venting the development of such microangiopathies 
and cardiovascular diseases in order to improve the 
long-term prognosis of diabetic patients. Among the 
classes of oral hypoglycemic agents, biguanides have 
been shown to improve the long-term prognosis of 
DM patients 2,3）. In addition, recent clinical studies 
have demonstrated that the sodium-glucose cotrans-
porter-2（SGLT2）inhibitors also reduced cardiovascu-
lar events and mortality in patients with T2DM 4,5）. 
However, the mechanism by which the SGLT2 inhibi-
tors inhibit the incidence of cardiovascular events is 
not fully understood.
On the other hand, it is recognized that the exis-
tence of chronic kidney disease（CKD）manifested by 
proteinuria and reduced renal function can not only 
progress to end-stage renal disease but also increases 
the risk of developing cardiovascular diseases 6,7）. Con-
sidering that DM is the major cause of CKD, the man-
agement of cardiovascular risks such as blood pres-
sure and blood glucose in diabetic CKD patients 
seems a matter of primary importance in clinical prac-
tice aiming at the maximum improvement of long-
term prognosis. The hypoglycemic effect of SGLT2 
inhibitors is supposedly lessened in patients with 
reduced renal function, however, there is an interest 
in if the cardiovascular risk is lowered by SGLT2 
inhibitors, because the co-existence of DM and CKD 
greatly increases the risk of developing cardiovascular 
events.
In the present study, we examined the effects of a 
SGLT2 inhibitor on the factors relating to the risks of 
cardiovascular diseases and renal injury in T2DM 
patients presenting CKD.
METHODS
The subjects enrolled in this study were 31 type 2 
diabetes mellitus patients with 7.0％ or higher hemo-
globin A1c（HbA1c）and/or 180 mg/dL or higher 
postprandial blood glucose and stage G1-G3 CKD. 
Patients with estimated glomerular filtration rate
（eGFR）lower than 30 mL/min/1.73 m2 or patients 
showing nephrotic level proteinuria were excluded 
and patients receiving insulin injection therapy or 
already taking a SGLT2 inhibitor were not included. 
The eGFR was calculated from the serum creatinine 
level and age by the following equation 8）：eGFR＝194
×Age－0.287×sCr－1.094（×0.739 for females）mL/min/ 
1.73 m2.
They were given 50 mg ipragliflozin once daily in 
the morning for 12 to 16 weeks in addition to other 
drugs which were not changed during the study peri-
od. Office blood pressure（BP）was measured with a 
sphygmomanometer in the sitting position after rest-
ing for at least 20 min at each visit every 4 weeks. 
Before and after 12 to 16 weeks of starting ipra-
gliflozin, non-fasting blood samples were drawn from 
the antecubital subcutaneous vein. In addition to the 
routine blood chemistry and blood cell counts, plasma 
B-type natriuretic peptide（BNP）was assayed using 
chemiluminescent enzyme immunoassay. Urine sam-
ples were also collected at the visits before and after 
12 to 16 weeks. Urinary albumin was measured by an 
immunoturbidimetric method and corrected using the 
urinary creatinine level. Then, the urinary albumin 
excretion（UAE）was expressed in mg albumin to g 
creatinine ratio（mg/gCr）.
The study protocol was in accordance with the rec-
ommendations of the World Medical Association for 
biomedical research involving human subjects（For-
taleza version, 2013）and was approved by the institu-
tional review board（No. 27032）. Informed consent 
was obtained from all subjects after explaining the 
study objective and design.
Clinical data were expressed as means±standard 
deviations（SD）. Statistical analyses were performed 
using Stat View software（version 5.0；SAS Institute 
Inc, Carey, North Carolina, USA）. Values before and 
after the study period were compared by paired 
t-test. However, Wilcoxon signed-rank test was 
applied for the data with skewed distribution. A P 
value of less than 0.05 was considered to be statisti-
cally significant.
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RESULTS
Among the 31 patients who started ipragliflozin, a 
67-year-old women stopped taking ipragliflozin after 
3 days because of pollakisuria and she withdrew the 
consent to continue the study protocol. Other 30 
patients showed good adherence to the therapy and 
fulfilled the whole study periods. Table 1 shows the 
baseline characteristics of these 30 patients. The 23 
patients were overweight with body mass index
（BMI）higher than 25 kg/m2 of which 10 had obesity 
with BMI higher than 30 kg/m2 resulting in the group 
mean BMI as overweight level. The majority of 
patients were accompanied with other lifestyle-related 
diseases such as hypertension, dyslipidemia and 
hyperuricemia.
Table 2 lists the drugs concurrently prescribed dur-
ing the study period of 12 to 16 weeks. Although the 
patients under insulin injection therapy were exclud-
ed, 28 of 30 patients were taking oral hypoglycemic 
agents other than SGLT2 inhibitors. Dipeptidyl pepti-
dase 4 inhibitors were most frequently used followed 
by a-glucosidase inhibitors and glinides. Because the 
study subjects include a considerable number of 
patients with reduced renal function, few patients 
were given biguanides, sulfonylureas or thiazolidine 
derivatives. As antihypertensive medications, angio-
tenisn II receptor blockers and calcium channel block-
ers were frequently used to lower blood pressure and 
reduce proteinuria.
The physical findings of study subjects before and 
after taking ipragliflozin are shown in Table 3. Body 
weight was significantly reduced by 1.8 kg during the 
12 to 16 weeks of giving ipragliflozin. Systolic and dia-
sto l ic BPs were also s igni f icant ly reduced by 
10.4/6.2 mmHg after taking ipragliflozin for 12 to 16 
weeks. On the other hand, the heart rate was not sig-
nificantly changed by ipragliflozin administration.
Table 4 shows the changes in blood cell counts 
before and after 12 to 16 weeks of starting ipra-
gliflozin. The number of erythrocytes, hemoglobin 
concentration and hematocrit were significantly 
increased suggesting the occurrence of dehydration 
and hemoconcentration by the ipragliflozin treatment. 
The changes in blood chemistry data are shown in 
Table 5 . As naturally expected, highly significant 
reductions in non-fasting blood glucose and HbA1c 
were observed after taking ipragliflozin for 12 to 16 
weeks. The liver enzymes such as aspartate transami-
nase（AST）, alanine transaminase（ALT）, g-glutamyl-
transferase（g-GTP）were also reduced significantly at 
the end of study period. Although the serum proteins 
were not significantly changed and the change in 
Table 1　Baseline characteristics of the study subjects
Age, years 63.5±11.3
Gender, male/female 18/12
Body mass index, kg/m2 28.0±4.8
Systolic blood pressure, mmHg 131.4±13.2
Diastolic blood pressure, mmHg 78.9±12.5
Heart rate, bpm 76.7±11.3
Duration of diabetes mellitus, years 10.3±10.4
Complications
　Hypertension 25（83％）
　Dyslipidemia 23（77％）
　Hyperuricemia 12（40％）
　Coronary artery disease  5（17％）
　Arrhythmia  4（13％）
　Chronic glomerulonephriis  3（10％）
Data are the mean±SD.
Table 2　 Medications concurrently given with ipragliflozin 
in study subjects.
Drug
Number of  
subjects（％）
Oral hypoglycemic agent
　Biguanide
　Thiazolidine derivatives
　Sulfonylurea
　Glinide
　Dipeptidyl peptidase 4 inhibitor
　a-glucosidase inhibitor
 5（17％）
 1（3％）
 3（10％）
 8（27％）
24（80％）
13（43％）
Antihypertensive drug
　Diuretic
　b-blocker
　Other adrenergic inhibitor
　Calcium channel blocker
　ACE inhibitor
　Angiotenisn II receptor blocker
 9（30％）
 9（30％）
 4（13％）
18（60％）
2（7％）
27（90％）
Lipid-lowering drug 23（77％）
Antihyperuricemic drug 12（40％）
Antiplatelet drug  9（30％）
Anticoagulant  3（10％）
Antianginal drug  5（17％）
Antiarrhythmic drug 1（3％）
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Table 3　 Blood pressure, heart rate and body weight before and after 12 to 16 
weeks after starting ipragliflozin
Variable Before After 12-16 weeks P value
Systolic BP, mmHg 131.4±13.2 121.0±11.4 ＜0.001
Diastolic BP, mmHg 78.9±12.5 72.7±10.5 ＜0.001
Heart rate, bpm 76.7±11.3 74.6±11.4 　0.127
Body weight, kg 73.2±14.3 71.4±14.2 ＜0.001
Data are the mean±SD. BP, blood pressure.
Table 4　 Peripheral blood cell counts before and after 12 to 16 weeks after starting 
ipragliflozin
Variable Before After 12-16 weeks P value
White blood cell, ×10 3/mm3 7.64±1.88 7.89±1.51 　0.543
Red blood cell, ×10 6/mm3 4.59±0.75 4.90±0.71 ＜0.001
Blood hemoglobin, g/dL 13.7±2.2 14.5±2.2 ＜0.001
Hematocrit, ％ 41.1±6.2 44.1±6.2 ＜0.001
Platelet, ×10 3/mm3 235±60 230±40 　0.526
Data are the mean±SD.
Table 5　 Data of blood chemistry before and after 12 to 16 weeks after starting 
ipragliflozin
Variable Before After 12-16 weeks P value
Aspartate transaminase, U/L
［min-max］
26±14
［10-79］
23±9
［11-53］
　0.002
Alanine transaminase, U/L
［min-max］
33±24
［11-108］
29±21
［7-106］
　0.002
g-glutamyltransferase, U/L
［min-max］
47±51
［12-288］
39±46
［11-263］
　0.001
Total protein, g/dL 7.0±0.5 7.1±0.5 　0.093
Albumin, g/dL 4.0±0.4 4.1±0.4 　0.134
Na, mEq/L 139.5±3.0 140.6±2.1 　0.020
K, mEq/L 4.3±0.4 4.4±0.5 　0.214
Urea nitrogen, mg/dL 21.8±10.7 23.2±10.4 　0.082
Creatinine, mg/dL 1.24±0.47 1.32±0.56 　0.010
Uric acid, mg/dL 6.3±1.4 5.6±1.2 ＜0.001
Plasma glucose, mg/dL 166±33 146±34 　0.004
Hemoglobin A1c（NGSP）, ％ 7.5±0.7 6.9±0.7 ＜0.001
HDL-cholesterol, mg/dL 50±16 51±15 　0.628
LDL-cholesterol, mg/dL 105±44 105±41 　0.463
Triglycerides, mg/dL
［min-max］
192±88
［70-409］
167±72
［65-347］
　0.028
Data are the mean±SD. AST：aspartate transaminase, ALT：alanine transaminase, 
g-GTP：g-glutamyltransferase, HDL：high-density lipoprotein, LDL：low-density 
lipoprotein, NGSP：National Glycohemoglobin Standardization Program.
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serum urea nitrogen was not significant, serum sodi-
um and creatinine were significantly increased after 
the 12 to 16 weeks of ipragliflozin therapy. As for the 
serum lipids, the triglycerides were significantly 
decreased, although the levels of high-density lipopro-
tein（HDL）- and low-density lipoprotein（LDL）-cho-
lesterols were not affected by ipragliflozin.
Figure 1 shows the changes in HbA1c in patients 
grouped by eGFR levels. Ipragliflozin, a SGLT2 inhibi-
tor, significantly lowered HbA1c in CKD patients with 
reduced renal function, namely stage G3a（eGFR 
45-59 mL/min/1.73 m2）and stage G3b（eGFR 30-44 
mL/min/1.73 m2）, as well as in patients with 60 mL/
min/1.73 m2 or higher eGFR.
Figure 2 depicts the change in plasma BNP before 
and after taking ipragliflozin. The plasma BNP was 
significantly reduced from 52.6±59.4 pg/mL to 46.2±
62.1 pg/mL（p＝0.020）after the 12 to 16 weeks of 
Figure 1　 Changes in hemoglobin A1c（HbA1c）before and after taking ipragliflozin for 12 to 
16 weeks in CKD patients grouped by the stage of eGFR reduction；G1-2 ≥ 60, 
G3a 45-59 and G3b 30-44 mL/min/1.73 m2. Data are mean±SD.
Before After12-16 wk Before
After
12-16 wk Before
After
12-16 wk
HbA1c 
(%) p=0.022
p=0.002
p=0.004
G1-2 G3a G3b
Figure 2　 Changes in plasma B-type natriuretic peptide（BNP）
before and after taking ipragliflozin for 12 to 16 
weeks. Data are mean±SD.
pg/mL
SD 
p=0.020
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ipragliflozin administration. Figure 3 shows the chang-
es in parameters of nephropathy. Although the serum 
creatinine was significantly increased, the decrease in 
calculated eGFR was minimal and insignificant, from 
to 48.8±19.0 to 47.3±20.0 mL/min/1.73 m2（p＝0.117）
after taking ipragliflozin for 12 to 16 weeks（Figure 3, 
left panel）. On the other hand, the UAE was signifi-
cantly reduced from 1200±1828 to 928±1436 mg/
gCr（p＝0.018）by the 12 to 16 weeks ipragliflozin 
treatment（Figure 3, right panel）.
DISCUSSION
In the present study, the long-term treatment with 
a SGLT2 inhibitor, ipragliflozin, not only improved 
blood glucose control but also reduced body weight 
and blood pressure without increasing heart rate in 
diabetic patients with CKD. In addition, ipragliflozin 
significantly reduced serum uric acid, triglycerides, 
liver enzymes and plasma BNP. As to the indices of 
renal injury, serum creatinine was slightly increased, 
however, urinary albumin excretion was significantly 
reduced.
In diabetic patients complicated by CKD, the com-
prehensive management of cardiovascular risk factors 
is critically required because both DM and CKD are 
major risks for developing cardiovascular diseases and 
organ injuries. Therefore, alleviation of cardiovascular 
risk factors other than blood glucose should be consid-
ered in selecting the anti-diabetic drug therapy so as 
to improve the prognosis of such patients. Regarding 
the effects of oral hypoglycemic agents on the long-
term prognosis of diabetic patients, the United King-
dom Prospective Diabetes Study（UKPDS）has dem-
onstrated that the intensive blood-glucose lowering 
therapy with biguanide for an average of 10.7 years 
reduced all-cause mortality as compared with the 
control group with a diet therapy alone or the group 
given sulfonylureas 2）. The prospective study regis-
tered diabetic patients with atherothrombosis also 
showed the lower mortality in patients given bigua-
nide than those not given 3）. However, the evidence of 
improving the long-term prognosis such as mortality 
and the incidence cardiovascular events is lacking as 
to other classes of orally-administered hypoglycemic 
agents. Thereafter, the sodium-glucose cotransport-
er-2（SGLT2）inhibitors were introduced to the clini-
cal practice of managing diabetic patients and the 
large-scale randomized controlled trials such as the 
Empagliflozin Cardiovascular Outcome Event Trial in 
Type 2 Diabetes Mellitus Patients-Removing Excess 
Glucose（EMPA-REG OUTCOME）study 4） and the 
Canagliflozin Cardiovascular Assessment Study（CAN-
VAS）Program5） have shown that the SGLT inhibitors 
reduced the incidence of cardiovascular events and 
mortality.
As to the mechanism by which SGLT2 inhibitors 
reduce cardiovascular events, the facilitated urinary 
excretion of glucose is expected to cause osmotic 
diuresis and thereby reduce blood pressure and the 
risk of developing cardiovascular diseases. Although 
Figure 3　 Changes in estimated glomerular filtration rate（eGFR, left panel）and urinary 
albumin excretion（UAE, right panel）before and after taking ipragliflozin for 
12 to 16 weeks. gCr：g creatinine. Data are mean±SD.
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SGLT2 inhibitor in chronic kidney disease46（2）（2019） 51
SGLT2 inhibitors facilitate water diuresis along with 
urinary excretion of glucose, the increase in urinary 
sodium excretion takes place transient and is not sig-
nificant after 24 hours a SGLT2 inhibitor is start-
ed 9,10）. This water diuresis rather than natriuresis 
induced by SGLT2 inhibitors may have caused the 
increase in serum sodium concentration observed in 
the diabetic patients given ipragliflozin in the current 
study. However, SGLT2 inhibitors have been shown 
to reduce body weight and blood pressure, as seen in 
the present study, and these effects are supposedly 
brought about by the diuretic effect 11,12）.
This diuretic effect of SGLT2 inhibitors is thought 
to contribute to reduce the incidence of heart failure. 
Patients with diabetes mellitus are at high risk of 
developing heart failure and their mortality is greatly 
increased by the presence of heart failure 13〜15）. Not 
only the incidence of heart failure with reduced ejec-
tion fraction but also the incidence of heart failure 
with preserved ejection fraction is increased in diabet-
ic patients and the existence of reduced left ventricu-
lar diastolic function also increases the mortality of 
patients 16〜18）. In the present study, plasma BNP, a 
marker of left ventricular load 19）, was significantly 
decreased by ipragliflozin in addition to body weight 
and blood pressure reductions. Also the large-scale 
clinical trials such as EMPA-REG4）, CANVAS Pro-
gram5） and Dapagliflozin Effect on Cardiovascular 
Events（DECLARE）20） have demonstrated that SGLT2 
inhibitors reduce hospitalization due to heart failure in 
type 2 diabetic patients with cardiovascular risks. 
Thus, it seems certain that SGLT2 inhibitors reduce 
the risk of developing heart failure and the diuretic 
effect is involved in the mechanism of their preventive 
effects.
In the present study, blood hematocrit and hemo-
globin concentration were significantly increased after 
taking ipragliflozin. This may be understood as the 
results of hemoconcentration caused by the diuretic 
action of SGLT2 inhibitors. However, it has been 
reported that empagliflozin increased plasma erythro-
poietin in patients with type 2 diabetes 21）. It is specu-
lated that inhibition of tubular glucose reabsorption 
by SGLT2 inhibitors reduces renal energy and oxygen 
consumption which alleviates the hypoxia of renal 
interstitial tissue resulting in a decrease of inflamma-
tory cytokine release and potentiation of erythropoie-
tin production by the fibroblasts 22〜25）.
The serum creatinine concentration was significant-
ly increased after taking ipragliflozin for 12-16 weeks 
in the current study, although the change in eGFR 
was not significant. It has been also shown in the 
large-scale clinical trials such as EMPA-REG OUT-
COME and CANVAS Program that SGLT2 inhibitors 
transiently cause GFR reduction for a few months, 
however, the recovery of GFR value take place in the 
long-term treatment 26,27）. This GFR reduction is sup-
posedly caused by diuretic action of SGLT2 inhibitors. 
In addition, SGLT2 inhibitors have been shown to 
increase afferent arteriolar resistance and reduce 
intraglomerular capillary pressure which is supposed 
to result in a reduction of glomerular filtration 28,29）. 
This decrease in intraglomerular capillary pressure 
may cause GFR reduction on the one hand, but on the 
other hand it is expected to reduce albuminuria which 
is associated with the progression of nephropathy. 
Indeed, albuminuria was significantly reduced in the 
present study similar to EMPA-REG OUTCOME and 
CANVAS Program26,27）. According to the hyperfiltra-
tion theory, the increase in intraglomerular capillary 
pressure, glomerular hypertension, is assumed to play 
an important role in the development of diabetic 
nephropathy 30）. In EMPA-REG OUTCOME and CAN-
VAS Program26,27）, long-term renal outcomes such as 
doubling of serum creatinine and end-stage kidney 
disease requiring renal-replacement therapy is signifi-
cantly inhibited by SGLT2 inhibitors 26,27）. Therefore, 
the reduction of albuminuria by a SGLT2 inhibitor 
observed in this study supposedly implies renal pro-
tection in the long-term treatment of diabetic 
patients. This renoprotective effect is thought to bene-
fit especially to the CKD patients involved in this 
study presenting albuminuria/proteinuria and/or 
reduced renal function.
Thiazide and loop diuretics are generally used in 
the treatment of hypertension, heart failure and renal 
dysfunction. However, they sometimes cause adverse 
effects such as hypokalemia, hyperuricemia, dyslipid-
emia and impaired glucose tolerance. Importantly, it 
has been indicated that the occurrence of such 
adverse effects hampers the protective effects of 
diuretics against cardiovascular diseases 31,32）. Although 
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ipragliflozin exhibited diuretic effects reducing body 
weight and blood pressure in diabetic CKD patients in 
the present study, the change in serum potassium 
was insignificant and serum uric acid was significantly 
reduced . Probably , serum potass ium was not 
decreased because ipragliflozin mainly elicited water 
diuresis and the natriuretic effect was not prominent. 
Regarding the decrease in serum uric acid, it is specu-
lated that the inhibition of SGLT2 causes an increase 
in glucose reabsorption and uric acid excretion 
through glucose transporter 9（GLUT9）in the proxi-
mal tubuli 33）. These favorable effects of SGLT2 inhibi-
tors on the metabolism of electrolytes and uric acid 
seem advantageous in preventing cardiovascular dis-
eases in diabetic patients.
SGLT2 inhibitors have been also shown to exhibit 
favorable influence on serum lipid profile such as an 
increase in HDL-cholesterol although the changes in 
LDL-cholesterol and triglycerides seem inconsistent 11）. 
In the current study, serum triglycerides were signifi-
cantly decreased, while HDL- and LDL-cholesterols 
were not significantly changed. In addition, serum 
liver enzymes such as AST, ALT and g-GTP were 
significantly decreased by ipragliflozin. It is speculated 
that reduced load of carbohydrates to the liver reduc-
es production of triglycerides and deposition of lipid in 
the liver. The experimental studies have indicated 
that SGLT2 inhibitors lower inflammatory cytokines 
in the liver and inhibit the development of fatty liver 
in obese type 2 diabetic rats 34）. Considering that the 
cardiovascular risk is increased by the existence of 
nonalcoholic fatty liver disease 35）, these effects of 
SGLT2 inhibitors are supposed to benefit to prevent 
cardiovascular diseases in diabetic patients.
In summary, the present study showed that ipra-
gliflozin, a SGLT2 inhibitor, not only improved blood 
glucose control but also reduced body weight and 
blood pressure in type 2 diabetic patients with CKD. 
These effects are supposedly caused by its diuretic 
effect, however, usual adverse effects of diuretics such 
as hypokalemia was not observed and serum uric acid 
and triglycerides were rather decreased. As to the 
indices of renal injury, albuminuria was significantly 
decreased and the change in eGFR was minimal. It is 
suggested that these properties of a SGLT2 inhibitor 
are advantageous in controlling blood pressure as well 
as blood glucose and preventing cardiovascular diseas-
es and the progression of nephropathy in diabetic 
patients with CKD.
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